Association between the use of statins and evolution in dominant autosomal polycystic kidney disease

• Grant number: 17/02897-9
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: December 01, 2017
• End date: November 30, 2018
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Luis Cuadrado Martin
• Grantee: Maria Carolina Rodrigues Martini
• Host Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease. It is a frequent cause of renal function replacement therapy. It is characterized by progressive development of renal cysts, culminating with a renal failure in the middle age. Several therapeutic strategies looking for the delay of the growth of the renal cysts have been investigated, however, few have become therapies usable in humans. A study in children showed that pravastatin attenuated the speed of kidney growth, which represents a substitutive outcome in this disease. However, no study evaluated the effect of statins using as an outcome the renal terminal disease. Randomized and controlled trials about the DRPAD has the obstacle that its evolution is too slow, what would demand a long follow-up. Thus, an observational study with long follow-up is justified. Therefore, the objective of the current work is to analyze the association between the use of statins and outcomes in DRPAD. A longitudinal cohort study will be realized. The Cox analysis, with adjustment for the relevant confusion variables, will be used to evaluate an association between use of statins and combined endpoint of substitutive renal function therapy, double the creatinine or death of the patient. Will be evaluated all patients carriers of DRPAD attended at our institution for the first time between January 2002 and December 2014 and followed until June 2016. (AU)